ArticleInternational journal of particle therapy2025
Cost-Effectiveness of Proton Versus Photon Therapy for Medulloblastoma Using Updated Clinical Outcomes.
Article in International journal of particle therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Developing an automatic decision-assistance tool to choose proton/photon radiotherapy for patients with prostate cancer.Journal of applied clinical medical physics · 2026Article
- Inflammatory signatures across four photon radiotherapy and proton radiotherapy: mechanisms, mitigation, and quality of life impact.Exploration of targeted anti-tumor therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The benefit of proton beam therapy (PBT) is evident in pediatric cancer, as survivors have to face long-term radiation-related side effects and lifetime costs. However, PBT's higher costs cause a challenge especially in middle-income countries. This study analyzed cost-effectiveness of PBT versus photon beam therapy (XRT) for medulloblastoma based on updated clinical outcomes within middle-income country context. Materials and Methods: Markov and Monte Carlo models were constructed for simulation analysis. We used annual mortality rates based on actual medulloblastoma patients receiving craniospinal irradiation over the first 5 years, combined with general population mortality rates thereafter. Rates and utilities for side effects, including hormone deficiencies, hearing loss, brain tumors, thyroid cancer, and IQ decline, were derived from previous literature, while the cardiac mortality rate was estimated using a linear model. Medical and nonmedical costs, along with other economic parameters and mortality rates during the first 5 years, were derived within the context of a middle-income country, using Thailand as a representative setting where PBT is operational. Results: For the base-case model, the total costs for PBT and XRT were 69 349 USD (2 357 874 THB) and 80 217 USD (2 727 366 THB), respectively, with total utilities of 36.12 and 35.23, respectively. The ICER was -12 211 USD (-415 160 THB)/QALY, and the net monetary benefit for PBT and XRT were 100 627 USD (3 421 326 THB) and 85 572 USD (2 909 434 THB), respectively. Including microsimulation and probabilistic sensitivity analysis for side effects rates, mortality rates, inflation, cost reduction, and utility reduction, PBT was still cost-effective. However, XRT was found to be more cost-effective when excluding opportunity loss from IQ decline. Conclusion: Despite its higher cost, PBT was more cost-effective than XRT for treating medulloblastoma in a middle-income country, based on updated clinical outcomes, particularly when incorporating IQ decline into the analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.